• Pharmabiotics, the Conference of D&R (Development & Regulation)
    11th Edition will be celebrated on February 1–3, 2027 | Brussels
     

    The Pharmabiotics Conference is not just another scientific meeting. Now firmly established as the Conference of D&R (Development & Regulation): where Discovery is translated into Development, guided by Direction from Regulation, built on Dialogue across disciplines and with authorities, and driven by the Disruption that microbiome science brings to health, food systems, and sustainability.

    What sets this conference apart is its focus on regulatory case studies. With regulatory frameworks still under construction, researchers and developers share their journeys, real-world experiences that become practical case studies for the entire community. These insights are not only about presenting science, but about turning individual challenges into collective knowledge.

    This unique positioning is clearly reflected in the conference programme, where every session is grounded in rigorous science and shaped by the voices of industry, academia, and regulators. It is this combination of scientific depth and real-world perspective that makes Pharmabiotics a reference point for microbiome development and regulation in Europe and beyond.

    Backed by the Pharmabiotic Research Institute (PRI), an independent EU non-profit and recognized stakeholder, the conference ensures that the dialogue between science and regulation carries real weight with regulators, industry, and academia alike.
  • See you in

     

    147

    days

    :

    06

    Hour

    :

    23

    Minutes

    :

    54

    Seconds

  • WHY ATTEND?
     

    ► DiscoveryDevelopment: Translating science into real-world microbiome application or innovation .

    ► Direction: Providing Regulatory compass points in an emerging field where frameworks are still under construction, ensuring discoveries can be applied and advanced within the EU context.

    ► Dialogue: Creating a platform where researchers, regulators, and industry learn from each other’s journeys, accelerating the applicability of microbiome science across disciplines.

    ► Disruption: Showcasing how microbiome science and innovations reshape health, food systems, and sustainability.

    Join us in Brussels next February 2027 to honor the achievements of the past decade and chart the future of microbiome science through development and regulation.
  • Scientific Committee (2026 edition)

     
    Héloïse BRETON
    Director, Product management , DNA Genotek

    Pierre BURGUIERE, Strategic Senior Advisor
    Strategic Senior Advisor, US Pharmacopeia Microbiome Expert
     
    Hélène CVEJIC
    Full Professor, University of Novi Sad
    Katja CONRATH
    CSO, MRM Health
    Marco PANE
    R&D Director, Probiotical SPA
    Sylvie BINDA
    R&D Vice President, Lallemand Health Solutions
    Nail NASIR
    CSO, Astel Medica
    Luc STERKMAN
    CEO, Caelus Health
    Ana PALMEIRA
    Professor, University Beira Interior
    Christian ROGHI
    Microbiome Strategy and Innovation Consultant, Big Bold Bridges Consulting
    Sandrine CLAUS
    CEO, Starfish Bioscience
    Julie RODRIGUEZ
    OMICS Project Manager, PRI
    Celine DRUART
    Executive Director, PRI
  • Organized by

     
  • The Pharmabiotic Research Institute (PRI) is Europe’s leading organisation dedicated to microbiome regulatory science. Established in 2010 as a non-profit association, PRI works to advance microbiome-based innovation by helping researchers, developers, regulators, and policymakers navigate the scientific and regulatory pathways required to bring microbiome products to market.

    With more than 70 members from industry and academia, PRI represents Europe’s largest microbiome regulatory science network, covering nearly every stage of the product development lifecycle. Through its collaborative “Share & Learn” model, PRI identifies regulatory gaps, develops scientific consensus, and fosters dialogue with competent authorities to support the safe, effective, and timely development of microbiome-based innovations.

    By advancing regulatory science, contributing to standards and policy discussions, facilitating pre-competitive collaboration, and helping regulators and policymakers understand the scientific and technical specificities of microbiome-based innovations, PRI works to clarify the scientific and regulatory requirements relevant to microbiome-based innovations.  Through these activities, alongside its direct support and mentorship of members, PRI helps reduce regulatory uncertainty, de-risk innovation, and accelerate the translation of microbiome research into products and solutions that benefit health, food systems, and environmental sustainability.

     
  • Event PlanneR
    Registration contact
    INSIGHT OUTSIDE
    26 av Jean Kuntzmann - 38330 Montbonnot, France
    Tel : +33 825 595 525 (0,15€/min*)
    Information desk: Monday to Friday
    from 9:00 to 12:00 and 14:00 to 17:00
    (*) Prices starting from fixed line incumbent, a surcharge may be applied by operators, counting the second after the first 45 seconds.

    According to France's Personal Data Privacy Act in effect since June 2004, you may send a request in writing to INSIGHT OUTSIDE 26 Avenue Jean Kuntzmann, 38330 - Montbonnot / France, or by email webmaster@insight-outside.fr to access your file in order to consult, modify and/or delete your personal information.


    © 2005 - 2025 Insight Outside